HomeOpen Access NewsPharmaceutical Industry

Pharmaceutical Industry

Psilocybin and IBS treatment: First psychedelic study in gastroenterology

In a groundbreaking first, psilocybin is entering gastroenterology. Dr. Erin Mauney leads a pioneering study exploring how psychedelic therapy could transform treatment for millions suffering from treatment-resistant Irritable Bowel Syndrome, offering new hope for gut-brain disorders.

The use of medical cannabis in the UK

Andreas Met, COO, Compliance and Director at Halo Labs highlights how the use of medical cannabis is on the rise in the UK and could offer relief to many NHS patients.

The role of pharmacy during COVID-19

Gino Martini, RPS Chief Scientist and the Science and Research Team at the Royal Pharmaceutical Society reflect on the role of pharmacy during COVID-19 in delivering accessible, safe and effective care for all.

The UK’s clinicians need training in medical cannabis – here’s why

Professor Mike Barnes, Co-Founder of Maple Tree Consultancy states that the UK’s clinicians need training in medical cannabis and explains precisely why this should be.

Can the UK’s post-COVID-19 economy benefit from a booming medical cannabis industry?

Hannah Deacon, Co-Founder of Maple Tree Consultancy and Campaigner ponders if the UK’s post-COVID-19 economy can benefit from a booming medical cannabis industry.

EU Pharma Strategy: COVID-19 shows the need for diverse supply chains 

Rex Clements, CEO at Centrient Pharmaceuticals, discusses how the upcoming EU Pharma Strategy can prevent shortages and strengthen Europe’s manufacturing base, especially for antibiotics.

CBG: The mother of all Cannabinoids with broad antibacterial activity

Dr. Christian Löfke, researcher and product developer at BioBloom in Austria explains CBG (cannabigerol), a “new” cannabinoid with vast potential in cannabis research.

Ilesol Pharmaceuticals: First European cannabinoid à la carte company

Here, Ilesol Pharmaceuticals discuss how they became the first European cannabinoid company to unlock this sector of the market.

CBD: Narcotic substance or a novel food product?

CBD is at the forefront of pharmacology. So why has the European Commission changed its recommended status to “Narcotic”? Read on to find out more.

Stop drug testing and start impairment testing

A new public health app by DRUID® measures factors to give an overall score of impairment, evolving the classic idea of drug testing.

EUMCA: Limit of 0.2% THC in CBD products should not change

Chair of the European Medicinal Cannabis Association (EUMCA) issues warning that raising limit for THC in CBD to 0.3% will risk patient safety.

How are different types of medical cannabis working for different diseases?

Dr David Moorhouse, General Neurologist, discusses the way that different diseases respond to different types of medical cannabis.

How cannabinoids can be used as pain medicine

Dr Daniela Tonucci, a consultant for over 10 years, talks us through the use of cannabinoids as pain medicine.

The EUMCA: Pioneering access to medicinal cannabis

Professor Trevor Jones, Chair at the European Medicinal Cannabis Association, speaks to Nishat about their plans for EU patient access to medicinal cannabis.

Expanding the portfolio of rigorous cannabinoid research with new funding opportunities

David Shurtleff, PhD, Deputy Director at the National Center for Complementary and Integrative Health, National Institutes of Health, discusses new funding opportunities for cannabinoid research.

How does research in biochemistry fit into the wider goals of the NIH?

Open Access Government looks into the National Institute of General Medical Sciences (NIGMS)’s Biochemistry and Bio-related Chemistry Branch, and its current research areas and priorities.

Cytochromes P450: Chemistry for drugs, metabolism, and beyond

Joseph Najjar and Andrew K. Udit, PhD from the Department of Chemistry at Occidental College enlighten us on the importance of Cytochromes P450 in medicine and industry.

Advertisements


Latest Academic Articles

The latest academic articles from key research stakeholders